MS
FDMT icon

Maven Securities’s 4D Molecular Therapeutics FDMT Stock Holding History

Maven Securities’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,500
Closed -$271K – 1210
2020
Q4 		$271K Buy
+6,500
New +$268K 0.03% 444

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Maven Securities's FDMT Position: Q1 2021 in Review

Maven Securities sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 6,500 shares — an estimated $271K sold.

Maven Securities first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $271K in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

  • Maven Securities reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 6,500 4D Molecular Therapeutics shares in Q1 2021, an estimated $271K.
  • Maven Securities first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
  • Maven Securities's 4D Molecular Therapeutics position peaked at $271K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.